CoChat
Sign Up
Cited by 73Cardiovascular Function and Risk FactorsGenetics, Aging, and Longevity in Model OrganismsCardiovascular Disease and Adiposity

The DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index.

Obesity accelerates cardiovascular ageing

Open access
Ruperez, Celia, Madeo, Frank, de Cabo, Rafael, Kroemer, Guido, Abdellatif, Mahmoud·2025·European Heart Journal
DOI 10.1093/eurheartj/ehaf216PMC PMC12167665
Open this paper in CoChat — free account

Abstract

A global obesity pandemic, coupled with an increasingly ageing population, is exacerbating the burden of cardiovascular disease. Indeed, clinical and experimental evidence underscores a potential connection between obesity and ageing in the pathogenesis of various cardiovascular disorders. This is further supported by the notion that weight reduction not only effectively reduces major cardiovascular events in elderly individuals but is also considered the gold standard for lifespan extension, in obese and non-obese model organisms. This review evaluates the intricate interplay between obesity and ageing from molecular mechanisms to whole organ function within the cardiovascular system. By comparatively analysing their characteristic features, shared molecular and cell biological signatures between obesity and ageing are unveiled, with the intent to shed light on how obesity accelerates cardiovascular ageing. This review also elaborates on how emerging metabolic interventions targeting obesity might protect from cardiovascular diseases largely through antagonizing key molecular mechanisms of the ageing process itself. In sum, this review aims to provide valuable insight into how understanding these interconnected processes could guide the development of novel and effective cardiovascular therapeutics for a growing aged population with a concerning obesity problem.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaf216

Cites

295 of 295 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY-NC · PubMed Central
Figure 1 Trends of ageing, obesity, and cardiovascular disease between 1990 and 2021. This figure illustrates the rising trends in ageing, obesity, and cardiovascular disease over a 31-year period. It depicts the proportion of elderly and adults with obesity in Europe (WHO region) and globally, highlighting how these demographic shifts correlate with the increasing burden of cardiovascular diseases. Specifically, the figure shows the percentage of elderly individuals (≥65 years) as well as adults with obesity (BMI: >30 kg/m2) or cardiovascular diseases in Europe (A) and worldwide (B). Data on adults (>18 years) with obesity were extracted from the Global Health Observatory data repository (2024), World Health Organization.4 Data on population ageing and adults (≥20 years) with cardiovascular disease are from the Global Burden of Disease Study 2021 Results, Global Burden of Disease Collaborative Network.5
Figure 1 Trends of ageing, obesity, and cardiovascular disease between 1990 and 2021. This figure illustrates the rising trends in ageing, obesity, and cardiovascular disease over a 31-year period. It depicts the proportion of elderly and adults with obesity in Europe (WHO region) and globally, highlighting how these demographic shifts correlate with the increasing burden of cardiovascular diseases. Specifically, the figure shows the percentage of elderly individuals (≥65 years) as well as adults with obesity (BMI: >30 kg/m2) or cardiovascular diseases in Europe (A) and worldwide (B). Data on adults (>18 years) with obesity were extracted from the Global Health Observatory data repository (2024), World Health Organization.4 Data on population ageing and adults (≥20 years) with cardiovascular disease are from the Global Burden of Disease Study 2021 Results, Global Burden of Disease Collaborative Network.5CC BY-NC · PubMed Central
Figure 2 Common features of adverse cardiac remodelling in obesity and ageing at different levels of integration. Both obesity and ageing affect cardiac structure and function, regardless of the associated risk factors. Neurohormonal stress and abnormal haemodynamics are key contributors to left ventricular diastolic dysfunction and left atrial remodelling in obese and/or aged hearts. At the tissue level, these alterations coincide with increased myocardial hypertrophy, fibrosis, and stiffness. At the cellular level, cardiac cells in obese hearts display several hallmarks of ageing, including impaired autophagy and proteostasis, altered mitochondrial function, increased oxidative stress, DNA instability, and premature accumulation of senescent cells.
Figure 2 Common features of adverse cardiac remodelling in obesity and ageing at different levels of integration. Both obesity and ageing affect cardiac structure and function, regardless of the associated risk factors. Neurohormonal stress and abnormal haemodynamics are key contributors to left ventricular diastolic dysfunction and left atrial remodelling in obese and/or aged hearts. At the tissue level, these alterations coincide with increased myocardial hypertrophy, fibrosis, and stiffness. At the cellular level, cardiac cells in obese hearts display several hallmarks of ageing, including impaired autophagy and proteostasis, altered mitochondrial function, increased oxidative stress, DNA instability, and premature accumulation of senescent cells.CC BY-NC · PubMed Central
Figure 3 Common features of adverse vascular remodelling in obesity and ageing at different levels of integration. The vascular system of individuals with obesity exhibits structural and functional alterations reminiscent of those observed in aged individuals. Despite distinct underlying mechanisms, both obesity and ageing cause arterial lumen enlargement, impaired vasodilatory function, increased peripheral vascular resistance, and chronic activation of the RAAS system, increasing the risk of hypertension. At the tissue level, obesity accelerates atherosclerotic remodelling, intima–media thickening, and vascular stiffening and dysfunction. At the cellular level, insulin resistance, mitochondrial dysfunction, and ROS accumulation drive these pathological alterations. RAAS, renin–angiotensin–aldosterone system; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.
Figure 3 Common features of adverse vascular remodelling in obesity and ageing at different levels of integration. The vascular system of individuals with obesity exhibits structural and functional alterations reminiscent of those observed in aged individuals. Despite distinct underlying mechanisms, both obesity and ageing cause arterial lumen enlargement, impaired vasodilatory function, increased peripheral vascular resistance, and chronic activation of the RAAS system, increasing the risk of hypertension. At the tissue level, obesity accelerates atherosclerotic remodelling, intima–media thickening, and vascular stiffening and dysfunction. At the cellular level, insulin resistance, mitochondrial dysfunction, and ROS accumulation drive these pathological alterations. RAAS, renin–angiotensin–aldosterone system; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.CC BY-NC · PubMed Central
Figure 4 Meta-hallmarks of ageing and obesity in the cardiovascular system. This figure illustrates the shared molecular and cellular mechanisms between ageing and obesity that contribute to cardiac and vascular dysfunction, predisposing individuals to cardiovascular disease development and progression. These mechanisms include autophagy repression and loss of proteostasis (A), mitochondrial dysfunction and redox imbalance (B), DNA instability (C), cell senescence (D), altered neuro-hormonal signalling (E), and chronic inflammation (F). Features that are not shared are highlighted in red (if specific to obesity) or in blue (if specific to ageing) font. AngII, angiotensin-II; CRP, C-reactive protein; ER, endoplasmic reticulum; FA, fatty acids; IGF1, insulin-like growth factor 1; IL, interleukin; RAAS, renin–angiotensin–aldosterone system; ROS, reactive oxygen species; SASP, senescence-associated secretory phenotype; TNF, tumour necrosis factor; UPS, ubiquitin–proteasome system.
Figure 4 Meta-hallmarks of ageing and obesity in the cardiovascular system. This figure illustrates the shared molecular and cellular mechanisms between ageing and obesity that contribute to cardiac and vascular dysfunction, predisposing individuals to cardiovascular disease development and progression. These mechanisms include autophagy repression and loss of proteostasis (A), mitochondrial dysfunction and redox imbalance (B), DNA instability (C), cell senescence (D), altered neuro-hormonal signalling (E), and chronic inflammation (F). Features that are not shared are highlighted in red (if specific to obesity) or in blue (if specific to ageing) font. AngII, angiotensin-II; CRP, C-reactive protein; ER, endoplasmic reticulum; FA, fatty acids; IGF1, insulin-like growth factor 1; IL, interleukin; RAAS, renin–angiotensin–aldosterone system; ROS, reactive oxygen species; SASP, senescence-associated secretory phenotype; TNF, tumour necrosis factor; UPS, ubiquitin–proteasome system.CC BY-NC · PubMed Central
Figure 5 Common comorbidities in obesity and ageing. Obesity and ageing are associated with various pathological conditions that negatively impact cardiovascular and general health. These include, but are not limited to, hypertension, T2DM, vascular dementia, chronic kidney disease, sarcopenia, and osteoporosis. All of these conditions increase the risk of cardiovascular events and premature mortality, supporting the notion that obesity is an accelerator of cardiovascular ageing. CV, cardiovascular; T2DM, type 2 diabetes mellitus
Figure 5 Common comorbidities in obesity and ageing. Obesity and ageing are associated with various pathological conditions that negatively impact cardiovascular and general health. These include, but are not limited to, hypertension, T2DM, vascular dementia, chronic kidney disease, sarcopenia, and osteoporosis. All of these conditions increase the risk of cardiovascular events and premature mortality, supporting the notion that obesity is an accelerator of cardiovascular ageing. CV, cardiovascular; T2DM, type 2 diabetes mellitusCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–295 of 295

Cited by

Sorted by citations

See all 73

Related

See all

Metadata

Authors
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M.
Affiliations
  • Department of Cardiology, Medical University of Graz , Auenbruggerplatz 15, Graz 8036 ,
  • University of Graz (AT)
  • Translational Gerontology Branch, National Institute on Aging , Baltimore, MD ,
  • Inserm (FR)
Corresponding author
  • Kroemer, Guido
  • Abdellatif, Mahmoud
ORCID
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2025-04-08
Volume
46
Issue
23
Pages
2161-2185
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
DOI
10.1093/eurheartj/ehaf216
PMC
PMC12167665
OpenAlex
W4409261750
Cited by
73
References
295
Citations by year
2026: 53 · 2025: 20
FWCI
13.24
Type
journal article
Language
en
Open access
Licence
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
Funders
  • Medical University of Graz
  • BioTechMed-Graz
  • Austrian Science Fund
  • European Commission
  • FWF
  • ANR
  • Agence National de la Recherche (ANR-22-CE14-0066, ANR-23-CE44-0030, ANR-23-R4HC-0006)
  • Association pour la recherche sur le cancer
  • Cancéropôle Ile-de-France
  • Fondation pour la Recherche Médicale
  • European Joint Programme on Rare Diseases
  • European Research Council Advanced Investigator Award (101052444)
  • European Union Horizon 2020 research and innovation programmes Oncobiome (825410)
  • Prevalung (101095604)
  • Neutrocure (861878)
  • Hevolution Network on Senescence in Aging
  • Institut National du Cancer
  • Institut Universitaire de France
  • Mark Foundation
  • PAIR-Obésité INCa_1873
  • LUCA-pi (ANR-21-RHUS-0017, ANR-23-RHUS-0010)
  • Seerave Foundation
  • SIRIC Cancer Research and Personalized Medicine
  • Ministère des Solidarités et de la Santé
  • INSERM
  • University of Graz
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
obesity, cardiovascular aging, cardiovascular disease, weight loss, lifespan extension, metabolic intervention, cardiovascular therapeutics, older adults
MeSH terms
Aging, Animals, Cardiovascular Diseases, Humans, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review